You are here

  • Home
  • Archive
  • Volume 31, Issue Suppl 4
  • EPV129/#529 Long-term clinical and economic value of pembrolizumab + lenvatinib compared with chemotherapy in previously treated advanced endometrial cancer patients in Sweden: a cost-effectiveness analysis

Citation Tools

Article menu

Download PDFPDF

E-Posters
E-Poster Viewing
EPV129/#529 Long-term clinical and economic value of pembrolizumab + lenvatinib compared with chemotherapy in previously treated advanced endometrial cancer patients in Sweden: a cost-effectiveness analysis
Free

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Upadhyay N, Ralph L, Ljungcrantz C, et al
EPV129/#529 Long-term clinical and economic value of pembrolizumab + lenvatinib compared with chemotherapy in previously treated advanced endometrial cancer patients in Sweden: a cost-effectiveness analysis
International Journal of Gynecologic Cancer 2021;31:A81.